After its bumpy road with a thrice-failed Duchenne drug, the team at PTC Therapeutics has been busy putting new irons in its fire. In its latest effort, the New Jersey company announced Thursday that it’s acquiring a gene therapy startup with a few promising drugs in its pipeline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,